Source comparison
NAD+ Side Effects Long Term Research: Comparison
Nicotinamide Riboside (NR) 12 weeks to 24 months Mild GI symptoms (5–15%), transient nausea None documented; metabolic adaptation unknown Best-studied NAD+ precursor; clean short-term profile but human data caps at two years Nicotinamide Mononucleotide (NMN) 4
This comparison does not assign a generated winner or score.
- Nicotinamide Riboside (NR)
- 12 weeks to 24 months
- Mild GI symptoms (5–15%), transient nausea
- None documented; metabolic adaptation unknown
- Best-studied NAD+ precursor; clean short-term profile but human data caps at two years
- Nicotinamide Mononucleotide (NMN)
- 4 weeks to 12 months
- Minimal; occasional mild GI effects
- Insulin sensitivity changes in rodents not replicated in humans
- Promising early data but fewer long-term human trials than NR
- Niacin (Nicotinic Acid)
- Decades (cardiovascular use)
- Flushing (>80%), hepatotoxicity at high doses
- Well-established; not preferred for NAD+ restoration
- Long-term safety known but side effect burden too high for chronic NAD+ support
- NAD+ IV Infusion
- Single-dose or short-course
- Injection site reactions, transient fatigue
- Repeated high-dose exposure unstudied beyond 6 months
- Raises NAD+ acutely but lacks chronic dosing safety data